New CKM guideline urges team-based care, yet UH data show major therapy gaps; CINEMA model boosts outcomes amid cost, trust, and handoff hurdles.
|Articles|July 1, 1998
Supplements and Featured Publications
- New and Emerging Therapies in the Treatment of Hypertension and Congestive Heart Failure
- Volume 4
- Issue 7 Suppl
Rationale for Angiotensin Receptor Blockers in Congestive Heart Failure
Author(s)Alan H. Gradman, MD
Advertisement
Articles in this issue
about 28 years ago
Participating Facultyabout 28 years ago
Gene Polymorphism Influences Response to Angiotensin Blockadeabout 28 years ago
New Drug Class Offers Benefits in Heart Failureabout 28 years ago
Clinical Implications of Differences Between Angiotensin II AntagonistsAdvertisement
Related to this article
Obesity care surges with GLP-1 demand, but fragmented ownership, prior authorizations, and coverage rules stall treatment—pharmacists step in.
Roundtables reveal HFpEF/HFmrEF care lags despite rising cases; learn new SGLT2/MRA strategies, screening, and scalable team pathways.
Simple operational changes are proving more effective at closing gaps in cardiovascular-kidney-metabolic (CKM) syndrome care than education campaigns alone, according to panelists at at Population Health Roundtable
Panelists at AJMC roundtables in Philadelphia, Boston, Washington, DC, and Chicago traced why atopic dermatitis stays undertreated despite new therapies.
Eye care access for underserved patients with diabetes is limited and poorly understood. We identified barriers and innovative solutions to improve overall care and establish evidence-based practices.
Patient understanding should be treated as a measurable equity outcome, not an assumed byproduct of care.
Advertisement
Advertisement
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
3
FDA Expands Finerenone Approval to CKD Associated With Type 1 Diabetes
4
Oral GLP-1s, Medicare Bridge Reshape Obesity Care: Holly Lofton, MD
5